Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.

Inclusion Criteria:

• Men and women over 18
• Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up
• Patient not objecting to the REPRO-MICI study

Exclusion Criteria:

• Patients protected by law (pregnant or breast-feeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalised under duress).
• Patients with positive HIV, HBV or HCV serology.
• Patients with a positive ELISPOT with no history of treatment for latent tuberculosis.

Patients with IBD in severe relapse requiring hospitalisation for immunosuppressive therapy or endoscopy for relapse.